Statement of Changes in Beneficial Ownership (4)
March 17 2023 - 3:25PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Reid Laurence |
2. Issuer Name and Ticker or Trading Symbol
Decibel Therapeutics, Inc.
[
DBTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks |
(Last)
(First)
(Middle)
C/O DECIBEL THERAPEUTICS, INC., 1325 BOYLSTON STREET, SUITE 500 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/16/2023 |
(Street)
BOSTON, MA 02215
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/16/2023 | | A | | 195000 (1) | A | $0.00 | 220849 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Options (right to buy) | $3.73 | 3/16/2023 | | A | | 72000 | | (3) | 3/15/2033 | Common Stock | 72000 | $0.00 | 72000 | D | |
Explanation of Responses: |
(1) | Consists of shares of the Issuer's common stock issuable under 195,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025. |
(2) | Includes 195,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting. |
(3) | The option was granted on March 16, 2023. The shares underlying the option are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025. |
Remarks: President and Chief Executive Officer |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Reid Laurence C/O DECIBEL THERAPEUTICS, INC. 1325 BOYLSTON STREET, SUITE 500 BOSTON, MA 02215 | X |
| See Remarks |
|
Signatures
|
/s/ Jeffrey Schulz, Attorney-in-Fact | | 3/17/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Decibel Therapeutics (NASDAQ:DBTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Decibel Therapeutics (NASDAQ:DBTX)
Historical Stock Chart
From Jul 2023 to Jul 2024